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Summary The role of two common polymorphisms of enzymes involved in the metabolism of drugs and carcinogens was studied in relation
to prostate cancer. The gene encoding one of these enzymes (NAT2) is located in an area where frequent allelic loss occurs in prostate
cancer. Mutations at the genes CYP2D6 and NAT2 were analysed by allele-specific polymerase chain reaction and restriction mapping in
DNA from 94 subjects with prostate cancer and 160 male healthy control subjects. Eleven prostate specimens were analysed for genotype
and enzymatic activities NAT2, CYP2D6 and CYP3A by using the enzyme-specific substrates sulphamethazine and dextromethorphan.
Enzyme activities with substrate specificities corresponding to NAT2, CYP2D6 and CYP3A are present in human prostate tissue, with mean
± s.d. activities of 4.8 ± 4.4 pmol min-' mg-' protein, 156 ± 91 and 112 ± 72 nmol min-' mg-' protein respectively. TheKm, values for the prostate
CYP2D6 and CYP3A enzyme activities corresponded to that of liver CYP2D6 and CYP3A activities, and the CYP2D6 enzyme activity is
related to the CYP2D6 genotype. The N-acetyftransferase, in contrast, had a higher Km than NAT2 and was independent of the NAT2
genotype. The CYP2D6 and CYP3A enzymes, and an N-acetyttransferase activity that is independent of the regulation of the NAT2gene. are
expressed in human prostate tissue. The presence of carcinogen-metabolizing enzymes in human prostate with a high interindividual
variability may be involved in the regulation of local levels of carcinogens and mutagens and may underie interindividual differences in cancer
susceptibility.
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Prostate cancer is one ofthe most common cancers throughout the
world. and it is one of the major causes ofcancer-related deaths in
men in North America (Mahler. 1994) and Europe (Moller-Jensen
et al. 1990). Patient survival is hicher when the cancer affects the
glandonly. It has been show-n that screen-detected prostate cancers
are more frequently located in the gland only than clinically
detected cancers (Catalona et al. 1993). Therefore. earls detection
ofprostate cancer has become a topic ofmajor interest in the fields
ofpublic health and preventive medicine.
The aetiolocgx of prostate cancer is unknown and to date no
unequivocal biomarkers of susceptibility to prostate cancer haxe
been identified. Evidence for a genetic predisposition has been
found (Cannon et al. 1982). and familv histor- appears to be a
major risk factor to be considered (Narod et al. 1995). Segregation
analy-ses suggest that familial clustering of prostate cancer max be
caused by a high penetrance predisposition gene (Carter et al.
1992) the most likelx candidate genes are those located in regions
in w-hich allele loss occurs in prostate cancer. These regions are on
chromosomes 16q. lOq and 8p (Carter et al. 1990: Bergenheim et
al. 1991: Kunimiet al. 1991).
Here we have studied the relationship betw-een two polxmor-
phisms of enzymes that metabolize drugs and carcinogens. and
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prostate cancer risk. The polymorphisms studied have been
proposed as cenetic biomarkers for susceptibilitV to some forms of
cancer. It should be pointed out that the role of such polymor-
phisms on cancer risk should be considered as preliminary and
controversial. Howexer. the polymorphic CYP2D6 gene seems to
be inxolved in susceptibilitx to luna and liver cancer (AgIndez et
al. 1995a: Bouchardx et al. 1996). .VA72 is a gene of likelv impor-
tance in bladder and livercarcinogenesis. as subjects w-ith enzn-me-
inactivatinc mutations are at increased risk of dexelopinc bladder
and lixer cancer (Caporaso et al. 1991: Agtindez et al. 1996a). The
g-ene coding, for the NAT2 enzx-me is located in the short arm of
chromosome 8. in the same area in w-hich the most frequent allelic
loss occurs in prostate cancer tissue (Bergyenheim et al. 1991:
Franke et al. 1994: Vatsis et al. 1995). The loss of a aene codine
for an enzN-me involved in the detoxification of carcinogens or
mutag,ens could constitute a risk factor for carcinocenesis.
To date. no studies involxing a possible association of prostate
cancer and the polymorphisms studied here haxe been published.
Another point that has not been elucidated is whether the CYP2D6
and NAT2 enzymes are functionally expressed in human prostate
tissue. Expression of an N-acetxyltransferase actixity in rat and doc
prostate has been shown (Hein et al. 1991: Sone et al. 1994). but
the identitx of such an enzyme remains unclear. Recent studies
also indicate the presence of cytochrome P450 enzymes in human
prostate cancer tissues (Murrav et al. 1995). So far. most associa-
tions between polymorphic drug metabolizing enzymes and
carcinogenesis haxe been demonstrated in tissues in which the
enzymes are expressed (Caporaso et al. 1991). This is probably
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due to a strong local effect on the actixation or deactivation of
carcinogens in situ. For instance. it has been shovA-n that N-acetvl-
transferase polxmorphism plays a relevant role in the formation of
2-aminofluorene-DNA adducts in tumour target organs (Feng
et al. 1996). In an attempt to elucidate the events that occur as
previous steps to prostate carcinogenesis. x e haxe studied Ahether
the poix-morphic enzymes CYP2D6 and NAT2 are actixely
expressed in human prostate tissue. as well as the impact of such
genetic polx morphisms in prostate cancer susceptibility. In order
to ex aluate w-hether allelic loss of these genes occurs in adenoma-
tous prostate tissue. the occurrence of allelic losses at the CYP2D
and .VA72 gene loci in prostate tissues was also studied. If the
CYP2D6 enzyrme is functionally expressed in prostate. allelic loss
of CYP2D6 could cause changes in local enzyme activity. modi-
fving the local metabolism of carcinooens and mutarens. To our
know-ledge. no studies involving allelic loss of the polymorphic
gene CYP2D6 haxe been performed. This is also the first study
inxolxing allelic loss of the NVA72 gene in prostate. Indeed only
one study involvin2 allelic loss ofNAT2 has been published. and it
was performed in colon cancer (Hubbard et al. 1997).
METHODS
Patients and controls
All the subjects included in this studx were unrelated v hite
Spanish men. Ninety-four patients with prostate carcinoma. with
ages ranging from 56 to 93 years (mean ± s.d. 74.8 ± 7.6). and a
group of healthy subjects. composed of 160 men. aged 18-95
(mean± s.d. 45.4± 12.9). were included in the study. All the
cases were patients attendingr the Urology Service. San Carlos
Universitx Hospital. Madrid. All patients attending the Hospital
between March and December 1994 w-ere included in the study. As
all prostate cancer patients undergo a periodic health exaluation
every 6 months. virtually all patients diagrnosed w-ith prostate
cancer in the last years prior to the end of sample collection
(December. 1994) in the University Hospital were included in the
study group. The eligibility criteria included patients with
positive histological identification of prostate carcinoma and no
evidence of any other malignant disease. These included all ages
and all stages of disease. All patients requested arreed to partici-
pate in the study.
The control subjects w-ere recruited in the same area as the cases
(the centre of Spain). Over 98%7 of healthy subjects requested
agreed to participate in the study. Most of them were medical
students and staff from the Universitx Hospitals and participating
Unix ersities. All the control subjects were unrelated. in Qood
health and with no antecedents of disease. Informed consent was
obtained from all the participants. patients and control subjects
before their inclusion in the study. The protocol of this study was
approxed by the Ethics Committees of the Unixersity Hospital
Infanta Cristina (Badajoz. Spain) and the San Carlos University
Hospital (Madrid. Spain).
Venous blood samples (10-20 ml) were obtained from each
subject and collected in heparinized (sodium heparin 143 u.s.p.
units) sterile glass tubes (Vacutainer®. Becton Dickinson Systems
Europe. B.P. no. 37-38241 Meylan Cedex-France). and stored at
-80'C until DNA isolation. Samples of adenomatous prostate
tissue were obtained during surgery from patients attending the
same hospitals as the prostate cancer patients. The tissue samples
were immediately frozen and stored at-80C until analysis. Blood
Table 1 Individual values of N-acetyttransferase activities in prostate tissue
Sample Sulphamethazine
identification NAT2genotype Predicted NAT activity
phenotype (pmol min-' mg-1)
P01 NAT25B/NAT25B Slow 2.21 0.21
P02 NAT241NAT2*6A Intermediate 4.33 0.34
P03 NAT25BINAT26B Slow 15.68 0.37
P04 NAT24/NAT2'6A Intermediate 1.42 0.09
P05 NAT2W41NAT2'6A Intermediate 4.61 0.24
P06 NAT2'6A1NAT2'6A Slow 3.36 z 0.26
P07 NAT25BNAT2'12C Intermediate 2.25 0.12
P08 NAT2'4/NAT2'6A Intermediate 1.59 0.09
P09 NAT24/NAT2'4 Rapid 2.94- 0.31
P11 NAT2'5B/NAT2'5B Slow 10.6 0.7
P12 NAT25B/NAT2'6A Slow 3.53 0.4
The results are mean
- s.d. of at least three independent measurements.
These values were averaged in subgroups according to the NAT2 genotype
and are shown in the text.
Table 2 Individual values of CYP2D6 activities in prostate tissue
Sample CYP2D6 Predicted Dextrmetlhophan 0-
genotype phenotype denethylase
acbvit
(nmol min-' mg-,)
P01 CYP2D6'1/CYP2D6'1 Rapid 297 16
P02 CYP2D6'1/CYP2D6'2 Rapid 90 7
P03 CYP2D6'1/CYP2D6'1 Rapid 145 - 13
P04 CYP2D6'1/CYP2D6'1 Rapid 242 = 21
P05 CYP2D6'1/CYP2D6'1 Rapid 107 -32
P06 CYP2D6-1/CYP2D6-1 Rapid 190 7
P07 CYP2D6'1/CYP2D64 Intermediate 79 12
P08 CYP2D6-1/CYP2D6-1 Rapid 297 18
P09 CYP2D6-1/CYP2D6-1 Rapid 59 14
P11 CYP2D6'1/CYP2D65 Intermediate 48 8
P12 CYP2D62/CYP2D64 Intermediate 159 33
The results are mean - s.d. of at least three independent measurements.
These values were averaged in subgroups according to the CYP2D6
genotype and are shown in the text.
samples from the same patients w-ere obtained for comparison and
for the study of aenetic changes in the prostate tissue. Human liver
samples were used for comparison with the enzyme activities
identified in prostate tissue. These samples were biopsies obtained
from patients undergoinc surgery. as described elsewhere
(Agindez et al. 1990). The cytosolic and microsomal fractions
from prostate and liver tissues were performed as described else-
where (Agdndez et al. 1990: Grant et al. 1990).
Enzymatic assays
The analy ses ofenzy matic activities were carried out bx the use of
substrates specific for the NAT2 and the CYP2D6 enzymes. N-
acetyltransferase activity was anal sed by using sulphamethazine
as described elsewhere (Grant et al. 1990). The amount of parent
drug and the acetylated metabolite Aere determined bx high-
performance liquid chromatographv (HPLC) analysis (Grant
et al. 1990). The CYP2D6 activity was analysed by the use of
dextromethorphan (Kerrx et al. 1994). The standard reaction
mixture consisted of an NADPH regyenerating svstem (0.5 nm\
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NADPH. 50 mms glucose-6-phosphate and four enzxme units of
glucose-6-phosphate dehydrogenase). 5 mM\ magnesium chloride.
50 \iM dextromethorphan and 50-100 jg> of microsomal protein in
10 mnm Tris-HCl buffer. pH 7.5. in a final volume of 250 gl. The
reaction was started with the addition of microsomes and ,A-as
carried out at 37-C for 30 min. then stopped by the addition of
20 gl of 15% perchloric acid. The mixture was frozen for 30 min.
and centrifuged at 12 000 xg for 10 min. An aliquot of20 gl ofthe
supernatant w-as analysed for parent drug and metabolites by
HPLC analysis and fluorescence detection (Chen et al. 1990(.
Besides the CYP2D6 actixity. as calculated from the rate of
production of dextrorphan. the analvsis of the dextromethorphan
metabolite 3-methoximorphinan permits the determination of the
CYP3A activitx (Kerrv et al. 1994). Therefore. the measurements
of CYP3A actixitx in every prostate specimen w-ere carried out
under identical conditions to those ofCYP2D6 activity except that
the concentration of dextromethorphan x-as 4 mi\. For the Km
analvsis of the CYP3A actixity. dextrorphan instead of dextro-
methorphan was used (Kerrx et al. 1994). All the measurements
wxere performed at least in triplicate and in incubation time and
enzyme quantity linear conditions.
DNA isolation and analyses
Genomic DNA was purified from peripheral leucocytes and from
prostate tissues using standard protocols (Neitzel. 1986) and kept
in sterile plastic vials at 4'C until analx sis.
The NAT2 polymorphism was studied bx the use of a PCR-
based analysis. Which was carried out in txxo steps. First. a frag-
ment containing the coding region and a part of the 5' and 3'
flankinc regions of the NA4T2 ene was amplified (Agtindez et al.
1994). The 1213-bp product was used as a template for a set of
seven pairs of secondar- mutation-specific PCR reactions (one for
everv mutation studied). The association of several mutations in
the same allele w-as studied by mutation-specific PCR andlor
restriction mapping of the PCR products. The mutations studied
were: 191A. 282T. 341C. 481T. 590A. 803G and 857A. All these
mutations are within the coding rerion of the NAT2 gene. These
mutations. isolated or combined. have been reported as being
present in several allelic variants. all of which w-ere identifiable by
the methods used in this study (Agtndez et al. 1996b). Details
about the method used are described elsewhere (Martinez et al.
1995). The CYP2D6 genotyping was carried out by the combined
use of mutation-specific PCR and restriction mapping with the
enzymes EcoRI and XbaI as described elsewhere (Skoda et al.
1988: Gaediak et al. 1991: Tvndale et al. 1991: Heim and Meyer.
1991: Johansson et al. 1993). The analyses performed permitted
the identification of the allelic variants CYP2D6*1 )wild type).
two active allelic variants (CYP2D6*2 and CYP2D6*9). txo
defective allelic -ariants (CYP2D6*3 and CYP2D6*4) and the
occurrence ofcomplete gene deletion (CYP2D6*5) as well as gene
duplications or amplifications (CYP2D6*x2 and CYP2D6*>n).
Sequence analysis of the NAT1 gene in prostate
specimens
A fragment spanning the whole coding recion of the human MATi
gene. as vvell as 5' and 3' flanking regions. w-as amplified and
sequenced as follows. Genomic DNA obtained from all prostate
specimens w-as subject to a PCR amplification by using the
Table 3 Individual values of CYP3A activities in prostate tissue
Sample identfication Dextrometxrphan N-demethylase activity
(nmol mim-' mg-' protein)
Po1 278+12
P02 98 3
P03 78 12
P04 118 23
P05 82 17
P06 85 24
P07 110 5
P08 216- 11
P09 42 3
P11 39-5
P12 91- 7
The results are mean - s.d. of at least three independent measurements. In
the evaluation of the results no subgroups were made as no genetic
polymorphisms of the CYP3A activity has been shown. The results are
summarized in the text.
Table 4 NAT2 genotype in 94 patients with prostate cancer and 160 healthy
control subjects
Genotype Prostate cancer Healthy subjects
(% of subjects) (% of subjects)
NAT2'4/NAT2'4 10.6 6.9
NAT2'41NAT2'5A 2.1 1.2
NAT2'41NAT2'5B 12.8 21.2
NAT2'4/NAT2'6A 14.9 13.1
NAT2¶41NAT2'7B 1.1 2.5
NAT2'5BINAT2'5B 17.0 18.1
NAT2'5BINAT2'6A 19.1 23.8
NAT2'5B/NAT2'6B 2.1 0.6
NAT2'5BINAT27B 3.2 1.2
NAT2'6AINAT2'6A 6.4 3.8
NAT2'6AlNAT2'7B 3.2 1.9
Rare genotypes 6.4 5.6
Summary ofgenotype categones
Rapid/rapid 11.7 8.8
Rapid/slow 33.0 39.3
Slow/slow 55.3 51.9
Twenty different NAT2genotypes were identified in this study. Only those
present in 20% of subjects or over, either among cases or control subjects. are
listed in the table. The rest of the genotypes are induded in the group of rare
genotypes at the end of the table. The intergroup comparison analyses
indicate that no statistcally significant differences exist between cases and
control subjects. In all cases P-value was > 0.05. The relative risk ratio for
slow acetylators is 1.1 (950 Cl = 0.7-1.9).
primers TCAAATCCAAGTGTAAAAGT (position -62 to -43)
and GATACATGATAGGTCGTC [position 946 to 929 of the
NATI gene according to Blum et al (1990)]. PCR amplification
was carried out for 35 cycles of 1 min at 94-C. I min at 45-C and
I min at 72zC and a final extension period of 7 min at 72'C. The
amplified fragrment contains the mutations present in most allelic
x-ariants of the VATI gene. includinc the allelic -ariants N\ATJ *5.
4 ATI*11. NAT1*14. NIATI*15 and NATI*17. The allelic Xariant
NATi *4 (wild tvpe) is defined by the absence of mutations (for
a rexiexx. see Grant et al. 1997). Automated sequencinc of the
amplified fragments was carried out in an Abi Prism Mod. 310.
usincg a dRhodamine terminator cycle sequencing kit (Applied
Biosvstems. Foster Citv. CA. USA). Sequencing reactions were
carried out w-ith primers corresponding to the positions -62 to -43
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Table 5 CYP2D6 genotype in 94 pabents with prostate cancer and 160
healthy control subjects
Genotype Prostate cancer Healthy subjects
(% of subjects) (% of subjects)
CYP2D6'1 CYP2D6-1 62.8 63.1
CYP2D6'1 CYP2D6-3 1.1 2.5
CYP2D6'1 CYP2D6'4 13.8 16.9
CYP2D6'1 CYP2D6'9 5.3 3.7
CYP2D6'1 CYP2D6-5 6.4 2.5
CYP2D6-1 CYP2D6-,2 2.1 6.2
CYP2D64,CYP2D6'4 4.3 2.5
Rare genotypes 4.2 3.1
Summary ofgenotype categones
Rapid rapid 62.8 62.5
Rapid,slow 31 .9 33.7
Slow/slow 5.3 3.8
Twelve different CYP2D6 genotypes were identified in this study. Only those
present in 20o of subjects or over. either among cases or control subjects. are
listed in the table. The rest of the genotypes are included in the group of rare
genotypes at the end of the table. The intergroup comparison analyses
indicate that no statistically significant differences exist between cases and
control subjects. In all cases P-value was > 0.05. The relative risk ratio for
poor metabolizers is 1.4 (950o Cl = 0.4-4.6)
(direction 3'. 280 to 296 (direction ') and 946 to 929 (direction
5'.. accordin2 to the instructions of the manufacturer. Onlv three
allelic xariants of the X.AT] gene are not detected "-ith the method
used in this stud-. These are .XATI<3. V4AT110 and .VATI<16.
None of them induce amino acid changes and their impact on
NATI enz\-me actixvitv is doubtful (Grant et al. 1997).
Determination of loss of heterozygosity of the CYP2D6
and NAT2 genes
Patients >-ho %xvere heteroz\-gous for restriction mapping of the
CYP2D locus. or at the .\.IAT2 ene in anv point mutation (i.e. txxo
different sequences w-ere identified in the genotN-ping analv-ses)
x-ere analv-sed for loss ofheteroz\-Lositx-. The tests \vere achiexved
b\- Southern blot analvsis after digestion of the DNA w-ith restric-
tion endonucleases adequate for the mutation studied.
For CYP2D. the samples w-ere studied after digestion wxith the
enz\me EcoRl. and the Southern blot analv-sis wxas carried out as
described elsew-here b\- using as a probe the CYP2D6 cDN-A
that \vas kindly prox-ided by Professor tUrs A Meyer (Basle.
Sxx itzerland). Details of the method are described elsewxhere
(Johansson et al. 1993 I.
For the analysis ofY4AT2. a 931-bp PCR-amplified DNA fray-
ment obtained in the second amplification reaction of the .\AT2
aenotvping, (Martinez et al. 1995) x-as purified b\- agarose gel
electrophoresis. reamplified under identical PCR conditions and
used as a probe. The occurrence ofmutations at position 590 ofthe
gene causes loss of the laqI restriction site: therefore. the non-
mutated genes gixve digestion products of 664 and 267 bp. x-hereas
the mutated genes gixve a sinole band of 931 bp.
The probes for both genes analysed xxere labelled by random
priming xxith digoxigenin-ll-dUTP. using a digoxigenin DNA
labelling! and detection kit XBoehringer Mannheim. Barcelona.
Spain). Twxo DNA samples of exery subject. those obtained from
cenomic DNA from blood and prostate tissue. x-ere analxvsed in
parallel after digestion xxith the restriction endonucleases EcoRI
(CYP2D6 analysis and TaqI (NAT2 analxsis).
Statistical analyses
The intergroup comparison xalues xxere calculated by applx-ing the
X test. The 95%c confidence interxals xxere calculated according to
Bulpitt ( 1987). Exact tests xxere used xxhen required.
RESULTS
Enzyme activities in prostate tissue
CYP2D6. CYP3A and NAT2 enzN-me actixvitv xxas investigated in
adenomatous prostate tissue from 11 indixiduals. In these indixid-
uals the CYP2D6 and X\AT2 genotypes xxere deterrmined. besides
leucoc-xtic DNA. in DNA extracted from the prostate tissue. in
order to ensure the absence of anv genetic changes in the tissue
that could lead to mistyping of the samples. In all cases the geno-
types xxere concordant in blood and prostate DNA.
The mean ± s.e. xvalues for .-acet-ltransferase and CYP2D6 actix-
ities. as measured xxith enzx-me-specific substrates sulphamethazine
and dextromethorphan. xxere 4.8 ± 4.4 pmol m1in- mg-; protein
(range 1.4-15.7) and 156±91nmolmin-l mg-: protein (range
48-2971 respectixvely. N-acety-ltransferase actixit\ xxas not associated
xxith the number of actix-e .VAT2 genes. as shoxxn in Table 1. The
actixity. as expressed in pmol min' mg- protein. xa 2.9 ± 0.3 in a
specimen that had tx-o acti-e .\A72 genes. 2.8 ± 1.5 in fixe speci-
mens xxith one actixe gene and 7.1 5.8 in fixe specimens xxith
no actixve genes. thus indicating that the actixvitv is independent
of the .\.A2 genotyxpe. In contrast. the CYP2D6 actix itv shoxxs
a gene-dose effect xxhen compared xxith the CYP2ID6 genotxpe
(Table 2). The mean xalue for the eight samples xxith txwo actixve
genes xxas about tx-ofold higher ( 178 ± 93 nmol min' mg- protein)
than the actixvities in the three samples xx-ith one single actixe cene
(95 ± 57 nmol mnn-m mg- (.This is in accordance xxith the expression
of the CYP2D6 enz-me in hixer (Gonzalez et al. 1988). The differ-
ence observed xxas not statisticallx significant because of the small
sample size.
The method used for the determination ofCYP2D6 actixvitv also
permits the determination ofthe CYP3A actixitx. xxhich carries out
the N-demethvlation of dextromethorphan (Kerrx et al. 1994 As
no genetic polymorphism for CYP3A actixvity has been described.
all the samples xxere considered to belong to the same group (Table
3). The mean ± s.e. actixitx is 112 ± 72 nmol mmn- mg- protein
(range 39-278 ). This represents an enzyme actixvity about ten
times lowxer than that measured in human lixer microsomes (Kerrv
et al. 1994).
Genetic analyses of the CYP2D6 and NAT2
polymorphisms
All the DNA samples analysed xxere correctly amplified by PCR.
gixing DNA fragments of identical size. The stud! of point muta-
tions at the .\A72 gene in blood DNA samples rexvealed a similar
prexalence of mutations betw-een cases and control subjects. The
most common genotx pes identified are listed in Table 4.
Phenotxype prediction. accordina to the .VAT2 genotype (for a
rexviexx of actixe and defectixe .VAT2 alleles see Vatsis et al. 1995)
indicates that 52 out of the 94 patients xere slowx acetx-lators
(55.3%c. 95% CI. 45.2-65.3%c). Among control subjects the
frequency was almost identical: 83 subjects wxere classified as
slowx acetx lators (51.9%-. 95%- CI. 44.1-59.6%e
The restriction mapping analk-sis of the CYP2D locus aimed at
identifving complete gene changes. CYP2D6 gene deletions or
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Figure 1 Analyses of loss of heterozygosity at the CYP2D and NAT2 loci in
adenomatous prostate tissue. Top, the analysis of the sample P11 as
compared with P01. Lane 1. prostate DNA from an individual homozygous for
the CYP2D6'1 gene (sample P01): lane 2. blood DNA from the same
individual: lane 3. prostate DNA from an individual with the genotype
CYP2D6'11CYP2D6'5 (sample P11): lane 4, blood DNA from the same
indivdual. The alleles CYP2D6'1 and CYP2D6'5 are indicated by the
presence of bands of 9.4 and 13.0 kb respectively. Bottom. prostate and
blood DNA from individuals that were heterozygous (P08. lanes 1 and 2
respectively). homozygous for the presence of the restriction site (P01. lanes
3 and 4) and homozygous for the lack of the restriction site (P06. lanes 5 and
6 respectively). The band of 931 bp is caused by the lack of a restricton site.
and indicates the presence of a point mutation at the position 590. within the
coding region of the NAT2 gene
duplications that are not rare in w-hite subjects (Johansson et al.
1993: Agrindez et al. 1995b) and that w-ere present in nine 110% )
cases and 16 (10%) control subjects. Such analy-sis. as well as the
study of point mutations at the CYP2D6 gene. rexealed similar
prexalence ofgenotypes and allelic Xariants (Table 5) among cases
and control subjects. The phenotvpe prediction indicates that 5 out
of the 94 (5.3%. 95%7c CI. 0.8-9.8%7) and 6 out of 160 control
subjects (3.8%. 95%7e CI 0.8-6.7%/- ) wxere homozygous for defective
alleles and therefore classified as poor hydroxylators. The statis-
tical analvses indicate that the differences in the frequencies of
allelic xariants. or predicted phenotypes for both polyrmorphisms
studied. were not statistically significant. exen for single compar-
ison analysis. In all cases the chi-square analysis indicated a P-
xalue > 0.05.
Determination of loss of heterozygosity in
adenomatous prostate tissue
Only samples from subjects with heterozygous genotypes could be
analysed for loss of heterozvgositv. Thus. three tissue samples
showing heterozvogosity in the restriction fragment length poly -
morphism (RFLP) analysis ofthe CYP2D gene locus, namely P02.
... .
P11 and P12. were analy-sed for CYP2D6 allelic loss. Seven
samples with heterozygosity at the A.AT2 gene w-ere analy sed for
allelic loss. These were P02. P03. P04. P05. P08 and P12. For this.
Southern blotting of the DNA samples digested wxith adequate
restriction enzy-mes (see Methods) xwas performed and the comple-
tion of the digestion x as exaluated by comparing the band densi-
ties obtained in the DNA samples from blood and prostate. which
xwere digested and electrophoresed in parallel. After obtaining
semiquantitative Southern blot conditions. the band densities w-ere
compared in blood and prostate DNA. The complementar-
analvsis of the leucocv-te DNA rules out the possibility that
subjects with a complete allelic loss in prostate tissue w-ould be
misclassified as homoz-gous for the remainin2 allele. In such a
case. a discrepancy betx-een prostate and leucocyte DNA w-ould be
apparent. No such discrepancies A-ere observed. and no allelic
losses could be evidenced in any adenomatous prostate sample.
Figure 1 shows typical analyses of allelic loss at CYP2D6 and
.M4T2 renes.
Kinetic analyses of the enzyme activities identified in
prostate tissue
In order to assure the identity of the enzy-me actix-ities identified in
prostate tissue. a kinetic analy sis w-as performed to compare the Km
of prostate activities with that of the CYP2D6. CYP3A and NAT2
human lixer enz-mes. For this. microsomes (CYP2D6 and
CYP3A) and cvtosols (NAT2) from prostate samples and from
four human lixer biopsies were prepared as described under
Methods. FiVe out of 11 prostate samples with higher actixity for
ever- substrate were pooled for the Km analyses. For CYP2D6
enzyme the samples selected were PO1. P04. P06. P08 and P12.
For CYP3A the samples were PO1. P02. P04. P07 and P08. For
NAT2 the samples w-ere P02. P03. P05. P1I1 and P12. The lixer and
prostate preparations were analy sed w-ith identical substrates and
under identical conditions. as described under Methods. The K
xalues for the prostate CYP2D6 and the CYP3A enzyme actixities
(6 ± 3 g.tx and 3.6 ± 1.2 m-xi respectixely) A-ere identical to those
found in human lixer (5.5 ± 4 gr\ and 2.5 ± 1.5 m\o. therefore
indicatinc that these enzy mes have the same properties in prostate
tissue as those describ.ed in lixver. In accordance with the
phenotype-genotype discrepancy. the prostate .V-acetyltransferase
activity has a different Km Xalue (8 ±2 mix\t as compared with that
found in lixer (185 ± 43 g_\). This argues against the identitx ofthe
prostatic and lixer enzyme actix ities. indicating that the prostatic
enzyme is an N-acetvltransferase enzy-me different to that encoded
by the.XA12 gene.
Genetic analysis of the NAT1 polymorphism in prostate
specimens
Gixen the lack of association of the prostate A-acetyltransferase
activityxwith the NAT? genotype. we analysed the possible associ-
ation of mutations at the .\ATJ gene locus as a possible factor
influencing the enzyme actixitx. For this. the coding region and
flanking regions of the NAT] aene Aere sequenced in DNA
obtained from all prostate specimens w-hose N-acetyltransferase
w-as knowxn (Table 1). Only one sample contained mutations at the
.VATI locus. The prostate DNA sequence from the sample P05
indicates a multiple heterozyosity at positions -4OAT. 445G/A.
459G/A and 640 T/G. This is consistent Awith a NVATI*4NATJ*17
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genotype (Doll et al. 1997). Such heterozygosity was confirmed
by sequencing of the .'ATI gene from leucocyte DNA from the
same subject. The rest ofthe samples analysed had no mutations in
the studied DNA fragment. Therefore. the X-acetvltransferase
activity present in prostate tissue (Table I ) had no relationship to
mutations known to induce amino acid changes. or related to
changes of.ATJ activity in vivo or in v-itro (Grant et al. 1997).
DISCUSSION
The findings obtained in the present study indicate that enzymatic
acti-ities that may lead to regulation on the local levels ofcarcino-
gens and mutagens. nameiv CYP2D6 and CYP3A. are present
in human prostate tissue. In addition. an N-acetvltransferase
enzymatic activity is also present in human prostate.
WAhereas this is to our knowledge the first report indicating the
presence of CYP2D6 and CYP3A enzyme activities in prostate.
the occurrence ofan .V-acet-ltransferase activity in rat prostate has
already been demonstrated (Hein et al. 1991). Howvever. whether
this enzyme activity was present in human prostate tissue and. a
more relevant topic for cancer susceptibility. whether such activity-
is under the regulation of the .\AT2 gene (i.e. subject to genetic
polymorphism . remained to be elucidated. The present study
shows that the N-acetyltransferase activity present in prostate
tissue is not related to the .\AT2 or NATI genotypes. and therefore
seems to be the product of other gene) s It is to be noted that such
enzymatic activity has a high intenindividual variability (the
maximum and minimum activities are in a tenfold ranae). If such
enzyme activity is. like NAT2. able to metabolize carcinogens and
mutagens. it can be speculated that it may be a cause of inter-
individual variability in prostate cancer susceptibility. through V-
acetvlation pathways that are independent of N-AT] and APA2
regulation. Polymorphisms on genes encodincg enzymes involved
in the activation and deactivation of drugs and carcinogens have
been related to susceptibility to develop several forms of cancer
(for reviews see Caporaso et al. 1991: Evans. 1992: Caporaso and
Goldstein. 1995). The analyses of these polymorphisms as genetic
biomarkers ofsusceptibility may be used to determine the risks of
environmental exposures to susceptible individuals and popula-
tions (Hirvonen. 1995(. For instance. the association with bladder
cancer risk is supported bv a decreased clearance of low-dose
carcinogens in subjects with the slow acetvlator genotype (Vineis
et al. 1994). Recently we also described an association of low
NAT2 activity with primar- liver cancer (Agundez et al. 1996a>.
It should be pointed out that the enzyme poly-morphisms
analysed in the present study seem to be involved in carcinogen-
esis through the modulation ofthe levels ofactive carcinogens and
mutagens. although with apparently inverse effect. C-tochrome
P450 enzymes are usuallv involved in the activation of environ-
mental and food carcinogens. These include nitrosamines. afla-
toxin B 1. as well as polycyclic aromatic hydrocarbons and
heterocy-clic amines (Aoyama et al. 1990: Crespi et al. 1991:
Degawa et al. 1994: Yanagawa et al. 1994). Accordingly. subjects
with high CYP2D6 enzyme activity are at increased risk of devel-
opinc lung and liver cancer (Aguindez et al. 1995a: Bouchardv et
al. 1996). In contrast. NAT2 enzyme acts as a detoxifying system
for arvlamines and hvdrazines throurh N-acetvlation (Hein. 1988:
Guengerich. 1991: Hein et al. 1993). In fact. epidemiological
studies showed that the subjects with low NAT2 activity are at
increased risk of developing cancer of the bladder and larynx (for
a review, see Evans. 1992). In addition. the joint effects of NtAT]
and N.AT2 should be considered. as this 2ene-aene effect has been
reported for bladder carcinogenesis (Kloth et al. 1994: Badawi et
al. 1995: Kadlubar and Badawi. 1995). Our findings in prostate
specimens do not indicate anv association of N-acetvltransferase
activit- with the NAT] or the VAAT genotypes. or a joint effect
caused bv both of them.
Our findings indicate a lack of relationship between the A7M42
genotype and prostate cancer risk. This. together with the lack of
association between the N-acet-lation activitv and the .\AA geno-
tVpe in prostate tissue. virtually rules out anv major association
bet,ween the polvmorphism of the NAT2 enzyme and prostate
cancer risk. Our findings also indicate that. despite the presence of
CYP2D6. CYP3A and N-acetylation enzyme activities in prostate.
the poly-morphisms of the CYP2D6 and NAT2 enzymes are not
linked to a particular susceptibility to develop prostate cancer.
However. carcinogen-specificity analyses of the enzyme activities
present in human prostate tissue will be required to provide defin-
itive answers to whether these enzymes are involved in processes
ofactivation or deactivation ofcarcinogens and mutagens. thereby
beinc innvolved in the aetiology ofprostate cancer.
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